{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:49:51Z","timestamp":1794433791725,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.antiviral.2009.02.198","type":"journal-article","created":{"date-parts":[[2009,3,7]],"date-time":"2009-03-07T09:22:25Z","timestamp":1236417745000},"page":"95-102","source":"Crossref","is-referenced-by-count":417,"title":["T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections"],"prefix":"10.1016","volume":"82","author":[{"given":"Yousuke","family":"Furuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiyasu","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Smee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale L.","family":"Barnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin G.","family":"Julander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2009.02.198_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra0707279","article-title":"Update on avian influenza A (H5N1) virus infection in humans","volume":"358","author":"Abdel-Ghafar","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.02.198_bib2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/jm00206a005","article-title":"Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin)","volume":"21","author":"Allen","year":"1978","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2009.02.198_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.02.198_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2007.12.007","article-title":"Highly pathogenic RNA viral infections: challenges for antiviral research","volume":"78","author":"Bray","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2005.04.002","article-title":"Error-prone replication of West Nile virus caused by ribavirin","volume":"67","author":"Day","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib6","first-page":"883","article-title":"Natural and vaccine-induced immunity to foot-and-mouth disease: the prospects for improved vaccine","volume":"15","author":"Doel","year":"1996","journal-title":"O. I. E. Bull."},{"key":"10.1016\/j.antiviral.2009.02.198_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/vr.141.7.174","article-title":"Natural adoption to pigs of a Taiwanese isolate of foot-and-mouth disease virus","volume":"141","author":"Dunn","year":"1997","journal-title":"Vet. Rec."},{"key":"10.1016\/j.antiviral.2009.02.198_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0166-3542(94)90030-2","article-title":"Antiviral treatment of Argentine hemorrhagic fever","volume":"23","author":"Enria","year":"1994","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2007.11.002","article-title":"Treatment of Crimean\u2013Congo hemorrhagic fever","volume":"78","author":"Ergonul","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1086\/422000","article-title":"Characteristics of patients with Crimean\u2013Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy","volume":"39","author":"Ergonul","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.02.198_bib11","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib12","series-title":"Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother.","first-page":"199","article-title":"T-1106, a novel pyrazine nucleoside, hepatitis C virus polymerase inhibitor","author":"Furuta","year":"2004"},{"key":"10.1016\/j.antiviral.2009.02.198_bib13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/vr.149.24.729","article-title":"Descriptive epidemiology of the 2001 foot-and-mouth disease epidemic in Great Britain: the first five months","volume":"149","author":"Gibbens","year":"2001","journal-title":"Vet. Rec."},{"key":"10.1016\/j.antiviral.2009.02.198_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/oxfordjournals.epirev.a036250","article-title":"Serious morbidity and mortality associated with influenza epidemics","volume":"4","author":"Glezen","year":"1982","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.antiviral.2009.02.198_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2007.10.002","article-title":"Animal models of highly pathogenic RNA viral infections: hemorrhagic fever viruses","volume":"78","author":"Gowen","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib17","doi-asserted-by":"crossref","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","article-title":"Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin","volume":"3","author":"Gowen","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2009.02.198_bib18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1128\/AAC.01473-05","article-title":"Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters","volume":"50","author":"Gowen","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib19","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against Arenavirus and Bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.17.2.465-493.2004","article-title":"Foot-and-mouth disease","volume":"17","author":"Grubman","year":"2004","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2009.02.198_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1749-6632.2001.tb02682.x","article-title":"West Nile virus: Uganda, 1937 to New York City, 1999","volume":"951","author":"Hayes","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.antiviral.2009.02.198_bib22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2796.2006.01711.x","article-title":"Zoonotic viral diseases and the frontier of early diagnosis, control and prevention","volume":"260","author":"Heeney","year":"2006","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.antiviral.2009.02.198_bib23","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1128\/AAC.01494-06","article-title":"Activity of T-1106 in a hamster model of yellow fever virus infection","volume":"51","author":"Julander","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with a chemically related compound T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib25","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/427236","article-title":"Avian influenza viruses and their implication for human health","volume":"40","author":"Kaye","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.02.198_bib26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/clind\/24.4.718","article-title":"Treatment of Bolivian hemorrhagic fever with intravenous ribavirin","volume":"24","author":"Kilgore","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.02.198_bib27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/mol.105.020057","article-title":"The anti-yellow fever virus activity of ribavirin is independent of error-prone replication","volume":"69","author":"Leyssen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2009.02.198_bib28","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1086\/375058","article-title":"The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran","volume":"36","author":"Mardani","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.02.198_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.02.198_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.02.198_bib33","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: past, present and future","volume":"11","author":"Plotkin","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.02.198_bib34","first-page":"418","article-title":"The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105. FAO Report of the Research Group of the Standing Technical Committee of European Commission for the control of Foot-and-Mouth Disease, Paphos, Cyprus","volume":"64","author":"Sakamoto","year":"2006","journal-title":"FAO Appendix"},{"key":"10.1016\/j.antiviral.2009.02.198_bib35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.02.198_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In vitro and in vivo activities of T-705 and oseltamivir against influenza virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antivir. Chem. Chemother."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2009.02.198_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2006.01194.x","article-title":"Emerging viral diseases and infectious disease risks","volume":"12","author":"Tapper","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.antiviral.2009.02.198_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: the recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.antiviral.2009.02.198_bib39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1090350","article-title":"Are we ready for pandemic influenza?","volume":"302","author":"Webby","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.02.198_bib40","series-title":"Epidemic and Pandemic Alert and Response (EPR)","author":"WHO","year":"2008"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635420900240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635420900240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T13:02:20Z","timestamp":1589634140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635420900240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S016635420900240X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.02.198","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}